Skip to main content

Post-ASCO Summary: ctDNA as a patient selection and early efficacy marker in drug development

Our expert speakers will discuss the latest data from ASCO 2023 and other recent publications and congresses. This will be followed by a panel discussion on the future directions and implications for drug development and clinical trial design in this rapidly evolving space.